Novel HIV Treatment Approved
August 24th, 2007 by 
Barry - Admin BioPharmArena
FDA and Pfizer Inc. announced the approval of Selzentry, or maraviroc, the first agent in a new class of oral HIV medications: chemokine receptor 5 (CCR5) coreceptor antagonists.
By selectively blocking the CCR5 coreceptor, which is HIV’s predominant route of entry into T cells, maraviroc prevents CCR5-tropic HIV-1 from entering the cells. All other oral HIV treatments on the market combat the virus once it has already entered T cells, according to Pfizer.
According to the product’s FDA-approved labeling (PDF), Selzentry is indicated in combination with other antiretroviral medications for the treatment of adult patients with only CCR5-tropic HIV-1 detectable disease and evidence of viral replication despite treatment with other antiretroviral agents.
Posted in News, Global and Public Health, Regulatory Affairs | 